Secukinumab for treating moderate to severe plaque psoriasis: committee papers

Table of contents

01 Pre-Meeting Briefing prepared by NICE

02 Submission from the technology manufacturer - Novartis

03 NICE request to the manufacturer for clarification on their submission

04 Manufacturer clarification response

05 Consultee submission - British Association of Dermatologists

06 Consultee submission - Psoriasis Association

07 Consultee submission - Psoriasis and Psoriatic Arthritis Alliance

08 Clinical expert personal perspective - CHANDLER

09 Clinical expert personal perspective - MURPHY

10 Clinical expert personal perspective - SMITH

11 Evidence Review Group report prepared by Aberdeen HTA Group

12 Evidence Review Group report erratum

13 Manufacturer factual accuracy check of Evidence Review Group report


This page was last updated: 26 May 2015